SILENCE THERAPEUTICS PLC Silence Therapeutics Announces Board Change
April 16, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ('Silence' or 'the Company') a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today that Dr. Andy Richards, CBE, is leaving his role as interim non-executive Chair and a Director of the Company with immediate effect. The Company's previously announced process to appoint a new Chair is ongoing.
Dr. David Horn Solomon, Chief Executive Officer, commented:'Andy Richards has served on the Board of Silence since 2016, first as a non-executive director and more recently as interim Chairman. During this time, Andy has been instrumental in a implementing a bold turnaround of Company strategy which has re-energised our drug-development programmes and led us to a point where we are now preparing to commence in-human trials with our lead RNAi candidate SLN124. I would like to thank Andy for his invaluable contribution to the Company and wish him well in his future endeavours.'
Enquiries:
Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer Dr Rob Quinn, Interim Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson | Tel: +44 (0)20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Angela Gray silencetherapeutics@consilium-comms.com | Tel: +44 (0) 20 3709 5700 |
US IR Westwicke Partners Peter Vozzo Peter.vozzo@westwicke.com | Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit:https://www.silence-therapeutics.com/
Attachments
- Original document
- Permalink
Disclaimer
Silence Therapeutics plc published this content on 16 April 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 16 April 2019 10:27:02 UTC
